Author:
Baldini E,Prochilo T,Salvadori B,Bolognesi A,Aldrighetti D,Venturini M,Rosso R,Carnino F,Gallo L,Giannessi P,Conte P F,Orlandini C,Bruzzi P
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. A’Hern RP, Smith IE, Ebbs SR (1993) Chemotherapy and survival in advanced breast cancer patients: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67: 801–805
2. Baldini E, Salvatori B, Prochilo T, Bolognesi A, Aldrighetti D, Rosso R, Venturini M, Carnino F, Vicentini L, Gallo L, Mammoliti S, Giannessi P, Di Marsico L, Moyano A, Conte PF (2002) Epirubicin followed by paclitaxel vs epirubicin plus paclitaxel as first-line therapy in metastatic breast cancer (MBC): preliminary results from a multicenter randomised phase III trial. Proc Am Soc Clin Oncol 21: 52a (abstract 204)
3. Bashtold L, Dalmark M, Susanne BG, Pfeiffer P, Pedersen D, Sandberg E, Kjaer M, Mourisden HT, Rose C, Nielsen OS, Jakobsen P, Bentzen SM (1996) Dose–response relationship of epirubicin in the treatment of post-menopausal patients with metastatic breast cancer: a randomised study of epirubicin at four different dose levels performed by the Danish breast cancer cooperative group. J Clin Oncol 14: 1146–1155
4. Cersosimo RJ, Hong WK (1986) Epirubicin: a review of the pharmacology, clinical activity, and adverse affects of an Adryamicin analogue. J Clin Oncol 4: 425–439
5. Conte PF, Baldini E, Gennari A, Michelotti A, Salvadori B, Tibaldi C, Danesi R, Innocenti F, Gentile A, Dell’Anna F, Biadi O, Mariani M, Del Tacca M (1997) Dose-finding and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 15: 2510–2517
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献